OptiBiotix Health plc

("OptiBiotix" or the "Company")

New commercialisation partner in Asia Pacific

OptiBiotix Ltd, a wholly owned subsidiary of OptiBiotix Health plc (AIM: OPTI) and a life sciences business developing patented science and human study-based compounds that modulate the microbiome to address a range of health related issues such as metabolic syndrome and diabetes, systemic low-grade inflammation, obesity, cardiovascular disease, high cholesterol and healthy aging announces it has signed a services agreement with Nutraconnect for the Asia Pacific ("APAC") Region. Nutraconnect will develop and implement the go-to-market strategy for prebiotics ingredients SlimBiome® and LeanBiome®.

Nutraconnect Pte., Ltd. ("Nutraconnect"), is a nutraceutical business growth acceleration service headquartered in Singapore. The company provides end-to-end solutions for global nutraceutical ingredient manufacturers that are looking to establish a foundation for sustainable growth in the fragmented but growing APAC market. Nutraconnect possesses a wealth of experience in bringing innovative and science backed nutraceutical ingredients successfully to the market in the region.

René Kamminga, CEO of OptiBiotix Limited, commented: "Nutraconnect is an important extension of our commercial experience and reach in the APAC region. Nutraconnect brings unique regulatory and commercial experience combined with an extensive distribution and agency network in the various countries in the region. This partnership will help expedite the commercialisation of our prebiotic technologies in strategic countries in the region. At the same time, it will allow OptiBiotix to focus primarily on established key accounts and building up our North American presence and sales."

The Directors of the Company are responsible for the release of this announcement.

For further information, please contact:

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. 

This communication is a "Reach" announcement. Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained in this announcement is of a non-regulatory nature. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.